Vatinoxan Prevents Medetomidine-Associated Exophthalmos and Increased Glucose Concentrations in Blood and Aqueous Humor in Rats.

Authors

Minna P Mustikka, Emily K-M Lindh, Karoliina Alm, Anna S Meller, Pernilla E S Syrjä, Simon A Pot, Marja R Raekallio, Juhana Honkavaara

Published in

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. Pages 10807683261463884. Jul 14, 2026. Epub Jul 14, 2026.

Abstract

To evaluate whether vatinoxan, a peripherally selective alpha₂-adrenoceptor antagonist, prevents the acute, medetomidine-associated ophthalmic changes in rats.
Adult male Wistar rats (n = 9 in each group) were randomly allocated to receive subcutaneous medetomidine 0.4 mg/kg and midazolam 2 mg/kg (MM), MM with vatinoxan 8 mg/kg (MM-V), or MM with regular insulin 1 IU/kg (MM-I). Macroscopic photography (to assess globe position) and slit-lamp biomicroscopy were performed, and blood glucose (BG) concentration, intraocular pressure (IOP), and central corneal thickness (CCT) were measured at intervals until 50 min post-treatment. Surgical anesthesia was then induced, and aqueous humor glucose (AHG) concentration was measured prior to euthanasia.
In MM and MM-I, exophthalmos worsened over time (P < 0.05) and compared to MM-V (P ≤ 0.04 for both). BG increased significantly over time (P < 0.001) only in MM, and AHG was significantly higher in MM than in MM-V and MM-I (P < 0.001). Lens clarity was decreased at 50 min in both MM (P = 0.002) and MM-I (P = 0.048), compared to MM-V. CCT was greater in MM-V than in MM at 50 min (P = 0.02). Corneal clarity remained unchanged. IOP declined in all groups but remained significantly higher in MM-V 10 min versus 50 min post-treatment (P = 0.02).
Vatinoxan prevented pathological exophthalmos, lens opacification, the acute decline in IOP, hyperglycemia, and increased AHG in rats sedated with medetomidine-midazolam. Insulin similarly prevented hyperglycemia, but none of the ophthalmic changes. Acute alpha₂-adrenoceptor agonist-mediated ophthalmic pathologies are independent from glycemic control.

PMID:
42444493
Bibliographic data and abstract were imported from PubMed on 14 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.